The Latest Cardiac and Vascular News
The Bodyport Cardiac Scale is available to monitor heart function and fluid status in a single step at home SAN FRANCISCO–(BUSINESS WIRE)–Bodyport, a digital therapeutics company on a mission to address complex chronic conditions, announced today that its noninvasive biomarker platform, the Bodyport Cardiac Scale™ received U.S. Food & Drug […]
Modern Heart and Vascular Institute is proud to offer an intensive cardiac rehabilitation program designed to help patients get back to their normal lives after being diagnosed with cardiovascular disease. HUMBLE, Texas, Aug. 08, 2022 (GLOBE NEWSWIRE) — Modern Heart and Vascular is now offering intensive cardiac rehabilitation for patients […]
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value < 0.0001) decline on a placebo-adjusted basis, at 2 mg dose Independent Data Review Committee determined that the trial met pre-specified statistical criteria of overwhelming efficacy […]
Aligned with CHOP and AHA’s shared mission to improve cardiac care, grant supports research aiming to discover new hormones secreted from the heart PHILADELPHIA, Aug. 4, 2022 /PRNewswire/ — Children’s Hospital of Philadelphia (CHOP) has received a $400,000 grant from the American Heart Association (AHA) to help study heart-secreted hormones. The funding, which will be disbursed in yearly increments […]
LONDON–(BUSINESS WIRE)–AIBODY, the world’s first Physiology-as-a-Service platform, announced today that it has signed a collaboration agreement with the German Heart Centre Berlin (DHZB), a leading medical research institute specializing in cardiovascular disease. This agreement focuses on the development of a suite of innovative solutions that will facilitate the diagnosis and treatment […]
– Patisiran Met the Primary Endpoint with a Statistically Significant Improvement in 6-Minute Walk Test Compared to Placebo at 12 Months – – Patisiran Also Met the First Secondary Endpoint with a Statistically Significant Improvement in Quality of Life, as Measured by the Kansas City Cardiomyopathy Questionnaire, Compared to Placebo […]
NORRISTOWN, Pa.–(BUSINESS WIRE)–Thubrikar Aortic Valve, Inc., announced today successful 30-day outcomes in the first two patients receiving the Optimum Transcatheter Aortic Valve (Optimum TAV™). The implantations were performed by the Principal Investigator, Jaroslaw Trebacz, MD, at the Specialty Hospital Jana Pawla II, Krakow, Poland. The study was approved by the […]
Company to Distribute Recent FDA-Approved Treatment for Reducing Bad Cholesterol CORRECTION…by Soleo Health August 01, 2022 07:17 PM Eastern Daylight Time FRISCO, Texas–(BUSINESS WIRE)–Headline of release dated July 26, 2022, should read: Soleo Health Selected as Limited Drug Distribution Partner for Administration of LEQVIO® The updated release reads: SOLEO HEALTH […]
SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP® Cell Therapy Heart Failure Trial. “The Ottawa Heart […]
Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso® per session Achieved therapeutic levels by Month 2 and continued to titrate to higher levels for approximately one year on average before rolling into extension trial Safety […]
